Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spironolactone improves diastolic function in the elderly.

Chanwit Roongsritong1, Piraon Sutthiwan, Jason Bradley

  • 1Division of Cardiology, Texas Tech University Health Sciences Center, Lubbock, TX 79430-9410, USA. chanwit.roongsritong@ttuhsc.edu

Clinical Cardiology
|November 9, 2005
PubMed
Summary

Spironolactone treatment improved diastolic function in elderly individuals with isolated diastolic dysfunction. This study found significant improvements in mitral E/A ratio and deceleration time without serious adverse events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fair-weather friends. Sequential co-infection demonstrates priority effects in the outcome of <i>Parastagonospora nodorum</i> and <i>Pyrenophora tritici-repentis</i> polymicrobial foliar disease of wheat.

Plant disease·2026
Same author

Right Ventricular Outflow Conduit Stenosis After Childhood Ross-Konno Procedure.

JACC. Case reports·2025
Same author

Zero Coronary Artery Calcification: A Promising Value in Acute Chest Pain Evaluation.

Cureus·2025
Same author

Randomized Trial of Dietary Acid Reduction and Acid-Base Status of Patients With CKD and Normal Estimated GFR.

Kidney international reports·2025
Same author

Incidental Coronary Artery Calcification and the Risk of Major Adverse Cardiovascular Outcomes.

Cureus·2024
Same author

Kidney and Cardiovascular Protection Using Dietary Acid Reduction in Primary Hypertension: A Five-Year, Interventional, Randomized, Control Trial.

The American journal of medicine·2024

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Diastolic dysfunction is prevalent in the elderly, often linked to increased myocardial fibrosis with age.
  • Spironolactone has demonstrated the ability to prevent age-related myocardial fibrosis in animal models.

Purpose of the Study:

  • To investigate if spironolactone, through its antifibrotic properties, can enhance diastolic function in elderly patients with isolated diastolic dysfunction.

Main Methods:

  • A prospective, double-blind, randomized, placebo-controlled trial involving 30 elderly subjects (60-85 years) with isolated diastolic dysfunction.
  • Participants received either 25 mg/day of spironolactone or a placebo for 4 months.
  • Key measurements included mitral E/A ratio, deceleration time, plasma levels of carboxy-terminal of procollagen type I (PICP), and brain natriuretic peptide (BNP).

Related Experiment Videos

Main Results:

  • Spironolactone treatment led to significant improvements in the mitral E/A ratio and deceleration time compared to baseline.
  • No serious adverse events or clinically significant hyperkalemia were observed in the spironolactone group.
  • No significant differences in changes of PICP and BNP levels were noted between the spironolactone and placebo groups.

Conclusions:

  • Spironolactone shows potential as a therapeutic agent for improving diastolic function in the elderly population.
  • The antifibrotic effects of spironolactone may contribute to enhanced diastolic function in this demographic.